Medicine and Dentistry
Patient
100%
Neoplasm
60%
Nodular Melanoma
53%
Therapeutic Procedure
47%
Inpatient
30%
Dendritic Cell
29%
Ipilimumab
22%
Dendritic Cell Vaccine
22%
Placebo
21%
Analysis
20%
Adverse Event
20%
Pembrolizumab
18%
Combination Therapy
17%
Recurrent Disease
17%
Amaurosis
17%
Symptom
13%
Granulocyte Colony Stimulating Factor
13%
Metastatic Melanoma
13%
Angiopeptin
12%
Immunotherapy
12%
Monotherapy
12%
Surgery
11%
Vaccine
10%
Diseases
10%
Octreotide
9%
Overall Survival
9%
Immune Checkpoint Inhibitor
9%
DNA Repair
9%
Everolimus
9%
Papillary Thyroid Cancer
9%
Lymphatic Malformation
9%
Stromal Cell Derived Factor 1
9%
Systemic Therapy
9%
Messenger RNA
9%
DNA Damage Response
9%
Niraparib
9%
PARP Inhibitor
9%
Diseases
9%
Phase II Trials
9%
Progression Free Survival
9%
Diarrhea
8%
Cancer Cell
8%
Toxicity
8%
Seviprotimut L
8%
Survival
7%
Recurrence Free Survival
7%
Ovarian Cancer
7%
Disease Free Survival
7%
Tumor Microenvironment
7%
Progressive Disease
7%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
50%
Melanoma
47%
Ipilimumab
33%
Dendritic Cell Vaccine
22%
Malignant Neoplasm
19%
Placebo
19%
DNA
18%
Diseases
16%
Toxicity
15%
Adverse Event
14%
Metastatic Melanoma
14%
Recurrent Disease
13%
Granulocyte Colony Stimulating Factor
13%
Chemotherapy
13%
Pembrolizumab
13%
Blindness
11%
Immunotherapy
9%
Irinotecan
9%
Titanium
9%
Everolimus
9%
Hydralazine
9%
Abemaciclib
9%
Litronesib
9%
Nivolumab
9%
Pembrolizumab
9%
Dendritic Cell Vaccine
9%
Progression Free Survival
8%
Sodium Valproate
8%
Nivolumab
7%
Clinical Trial
7%
Monotherapy
7%
Ovary Cancer
7%
Overall Survival
7%
Vaccine
7%
Disease Free Survival
7%
Solid Malignant Neoplasm
7%
Taxane
7%
Maximum Tolerated Dose
7%
Tumor Microenvironment
7%
Pharmacokinetics
6%
Pegfilgrastim
6%
Ciprofloxacin
6%
Anticarcinogen
6%
Tilsotolimod
6%
Agonist
6%
Vemurafenib
5%
Disease Exacerbation
5%
Neutropenia
5%
Ifosfamide
5%
Mitogen Activated Protein Kinase Kinase Inhibitor
5%
Biochemistry, Genetics and Molecular Biology
DNA
43%
DNA Repair
37%
Cancer Cell
22%
Non-Homologous End Joining
20%
Homologous Recombination
20%
DNA Damage
19%
Histone Methylation
18%
Survival
16%
Histone H3
15%
Protein
15%
Transposase
13%
Cell Proliferation
12%
Topoisomerase
10%
BRCA1
10%
Lysine
10%
Association
9%
Phosphorylation
9%
Mutant
9%
R-Loop
9%
Poly ADP Ribose Polymerase
9%
DNA Damage Response
9%
Phase II Trials
9%
BAP1
9%
DNA Repair Protein
7%
Genome Instability
7%
Ubiquitin
7%
Ciprofloxacin
6%
Progression Free Survival
6%
Histone
6%
Cross-Link
6%
Primate
6%
